Freestone Capital Holdings’s Regeneron Pharmaceuticals REGN Stock Holding History

Freestone Capital Holdings’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$564K	Buy	904 +440	+95%	+$299K	0.01%	361
2026 Q1	$359K	Sell	464 -1	-0.2%	-$766	0.01%	405
2025 Q4	$359K	Hold	465	–	–	0.01%	393
2025 Q3	$261K	Hold	465	–	–	0.01%	455
2025 Q2	$244K	Sell	465 -73	-14%	-$40.7K	0.01%	396
2025 Q1	$341K	Sell	538 -83	-13%	-$57.1K	0.01%	337
2024 Q4	$442K	Buy	621 +9	+1%	+$7.55K	0.02%	300
2024 Q3	$643K	Buy	612 +6	+1%	+$6.68K	0.02%	259
2024 Q2	$637K	Buy	606 +14	+2%	+$13.6K	0.02%	266
2024 Q1	$570K	Buy	+592	New	+$563K	0.02%	285
2019 Q1	–	Sell	-967	Closed	-$361K	–	412
2018 Q4	$361K	Buy	+967	New	+$354K	0.02%	322

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Freestone Capital Holdings's REGN Position: Q2 2026 in Review

Freestone Capital Holdings increased its Regeneron Pharmaceuticals (REGN) stake by 95% in Q2 2026, buying an estimated $299K and bringing the position to 904 shares worth $564K. The position accounts for 0.01% of the portfolio, ranked #361.

Freestone Capital Holdings first reported a position in REGN in Q4 2018 and has held it in 11 quarters since. The position peaked at $643K in Q3 2024. 729 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Freestone Capital Holdings held 904 shares of Regeneron Pharmaceuticals worth $564K as of Q2 2026.
Freestone Capital Holdings bought 440 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $299K.
Regeneron Pharmaceuticals made up 0.01% of Freestone Capital Holdings's portfolio in Q2 2026, its #361 holding.
Freestone Capital Holdings first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 11 quarters since.
Freestone Capital Holdings's Regeneron Pharmaceuticals position peaked at $643K in Q3 2024.
729 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Freestone Capital Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.